Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

Lynk Pharmaceuticals Expands Commercialization Partnership with Simcere – Exclusive Greater China Rights for Zemprocitinib Extended to Atopic Dermatitis and Dermatological Indications
CompanyDeals

Lynk Pharmaceuticals Expands Commercialization Partnership with Simcere – Exclusive Greater China Rights for Zemprocitinib Extended to Atopic Dermatitis and Dermatological Indications

Lynk Pharmaceuticals announced the expansion of its commercialization partnership with Simcere Pharmaceutical Group Limited (HKG: 2096) for zemprocitinib, its in‑house developed, highly selective oral second‑generation JAK1 inhibitor. Under the new…

Lifetech Scientific Wins CE MDR Certification for IBS Absorbable Drug‑Eluting Coronary Stent – World's First Iron‑Based Bioresorbable Coronary Stent Approved

Lifetech Scientific Wins CE MDR Certification for IBS Absorbable Drug‑Eluting Coronary Stent – World’s First Iron‑Based Bioresorbable Coronary Stent Approved

Novartis Terminates BrainTransporter Collaboration with BioArctic – Program Discontinued, $30 Million Upfront Retained in Full

Novartis Terminates BrainTransporter Collaboration with BioArctic – Program Discontinued, $30 Million Upfront Retained in Full

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

GSK’s Ojjaara Approved by FDA for Anemic Myelofibrosis Patients

CompanyDeals

Eli Lilly Partners with Boundless Bio to Develop CHK1 Inhibitor for Solid Tumors

CompanyDrug

FDA Grants Priority Review to MSD’s Welireg for Advanced RCC Indication Extension

CompanyDrug

Astellas Pharma’s Xtandi NDA for mHSPC Treatment Accepted by China’s CDE

CompanyDrug

Zhejiang Medicine Gets NMPA Approval for NCB003 Clinical Study for Advanced Solid Tumors

CompanyDrug

Zelgen Biopharmaceuticals’ rhTSH Achieves Primary Endpoint in Phase III Study

CompanyDrug

Sandoz Receives Positive CHMP Review for Trastuzumab Biosimilar in HER2-Positive Cancers

CompanyDrug

Gilead’s Kite CAR-T Therapy Yescarta Achieves 71% CMR in Phase II Trial for R/R LBCL Patients

Show More